Author: Brandon Malone; Boris Simovski; Clement Moline; Jun Cheng; Marius Gheorghe; Hugues Fontenelle; Ioannis Vardaxis; Simen Tennoe; Jenny-Ann Malmberg; Richard Stratford; Trevor Clancy
Title: Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2: toward universal blueprints for vaccine designs Document date: 2020_4_21
ID: cm30gyd8_9
Snippet: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.21.052084 doi: bioRxiv preprint integrative CD8/CD4, and antibody immune parameters when designing a vaccine is also reinforced in an influenza mouse study which demonstrated that a universal T cell vaccine against Flu in the absence of a protective antibody response could result in a detrimental immunopathology in mice [27] . The importa.....
Document: The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.04.21.052084 doi: bioRxiv preprint integrative CD8/CD4, and antibody immune parameters when designing a vaccine is also reinforced in an influenza mouse study which demonstrated that a universal T cell vaccine against Flu in the absence of a protective antibody response could result in a detrimental immunopathology in mice [27] . The importance of an integrative CD8, CD4 and B cell response in mounting a successful immune response against the present SARS-CoV-2 threat was well established at an early stage [28] . Activated CD4 T cells and CD8 T cells, in concert with antibodies against SARS-CoV-2 were recruited in a successful fight against the virus and recovery in an infected patient [28] .
Search related documents:
Co phrase search for related documents- antibody response and cell vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibody response and detrimental immunopathology: 1
- antibody response and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- antibody response and immune parameter: 1
- antibody response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibody response and infected patient: 1, 2, 3, 4, 5, 6, 7, 8
- antibody response and influenza mouse: 1, 2, 3
- antibody response and protective antibody response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibody response and protective antibody response absence: 1
- antibody response and recovery virus: 1, 2
- antibody response and SARS antibody: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- antibody response and SARS threat: 1
- cell response and detrimental immunopathology: 1
- cell response and early stage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- cell response and Flu cell vaccine: 1
- cell response and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- cell response and infected patient: 1, 2, 3, 4, 5, 6, 7
- cell response and influenza mouse: 1, 2
- cell response and protective antibody response: 1, 2
Co phrase search for related documents, hyperlinks ordered by date